Global Multiplexed Diagnostics Market by Application (Infectious Disease Diagnostics, Allergies, Autoimmune Diseases, Cardiac Diseases, Oncology), by Technology (Very High Density Multiplexed Assays, Next-Generation Sequencing Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low Density Multiplexed Assays), by End User (Hospitals, Academic Research Institutes, Diagnostic Laboratories, Pharmaceuticals Companies, Clinical Research Organizations) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Multiplexed Diagnostics Market research report which is segmented by Application (Infectious Disease Diagnostics, Allergies, Autoimmune Diseases, Cardiac Diseases, Oncology), by Technology (Very High Density Multiplexed Assays, Next-Generation Sequencing Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low Density Multiplexed Assays), by End User (Hospitals, Academic Research Institutes, Diagnostic Laboratories, Pharmaceuticals Companies, Clinical Research Organizations), By Players/Companies Illumina Inc., Hologic Inc., Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd., bioMérieux SA, QIAGEN, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Luminex Corporation, Agilent Technologies”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Multiplexed Diagnostics Market Research Report |
| By Application | Infectious Disease Diagnostics, Allergies, Autoimmune Diseases, Cardiac Diseases, Oncology |
| By Technology | Very High Density Multiplexed Assays, Next-Generation Sequencing Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low Density Multiplexed Assays |
| By End User | Hospitals, Academic Research Institutes, Diagnostic Laboratories, Pharmaceuticals Companies, Clinical Research Organizations |
| By Companies | Illumina Inc., Hologic Inc., Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd., bioMérieux SA, QIAGEN, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Luminex Corporation, Agilent Technologies |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 222 |
| Number of Tables & Figures | 156 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Multiplexed Diagnostics Market Report Segments:
The market is segmented by Application (Infectious Disease Diagnostics, Allergies, Autoimmune Diseases, Cardiac Diseases, Oncology), by Technology (Very High Density Multiplexed Assays, Next-Generation Sequencing Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low Density Multiplexed Assays), by End User (Hospitals, Academic Research Institutes, Diagnostic Laboratories, Pharmaceuticals Companies, Clinical Research Organizations).
Multiplexed Diagnostics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Multiplexed Diagnostics Market
Overview of the regional outlook of the Multiplexed Diagnostics Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Multiplexed Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Multiplexed Diagnostics Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Infectious Disease Diagnostics
2. Allergies
3. Autoimmune Diseases
4. Cardiac Diseases
5. Oncology
7. By Technology:1. Very High Density Multiplexed Assays
2. Next-Generation Sequencing Assays
3. High Density Multiplexed Assays
4. Medium Density Multiplexed Assays
5. Low Density Multiplexed Assays
8. By End User:1. Hospitals
2. Academic Research Institutes
3. Diagnostic Laboratories
4. Pharmaceuticals Companies
5. Clinical Research Organizations
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Multiplexed Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Multiplexed Diagnostics Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Multiplexed Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Multiplexed Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Multiplexed Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Multiplexed Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Multiplexed Diagnostics Market Size & Forecast, 2018-2028
4.5.1 Multiplexed Diagnostics Market Size and Y-o-Y Growth
4.5.2 Multiplexed Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Multiplexed Diagnostics Market Analysis and Forecast by Application
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Application
5.1.2 Basis Point Share (BPS) Analysis by Application
5.1.3 Absolute $ Opportunity Assessment by Application
5.2 Multiplexed Diagnostics Market Size Forecast by Application
5.2.1 Infectious Disease Diagnostics
5.2.2 Allergies
5.2.3 Autoimmune Diseases
5.2.4 Cardiac Diseases
5.2.5 Oncology
5.3 Market Attractiveness Analysis by Application
Chapter 6 Global Multiplexed Diagnostics Market Analysis and Forecast by Technology
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Technology
6.1.2 Basis Point Share (BPS) Analysis by Technology
6.1.3 Absolute $ Opportunity Assessment by Technology
6.2 Multiplexed Diagnostics Market Size Forecast by Technology
6.2.1 Very High Density Multiplexed Assays
6.2.2 Next-Generation Sequencing Assays
6.2.3 High Density Multiplexed Assays
6.2.4 Medium Density Multiplexed Assays
6.2.5 Low Density Multiplexed Assays
6.3 Market Attractiveness Analysis by Technology
Chapter 7 Global Multiplexed Diagnostics Market Analysis and Forecast by End User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by End User
7.1.2 Basis Point Share (BPS) Analysis by End User
7.1.3 Absolute $ Opportunity Assessment by End User
7.2 Multiplexed Diagnostics Market Size Forecast by End User
7.2.1 Hospitals
7.2.2 Academic Research Institutes
7.2.3 Diagnostic Laboratories
7.2.4 Pharmaceuticals Companies
7.2.5 Clinical Research Organizations
7.3 Market Attractiveness Analysis by End User
Chapter 8 Global Multiplexed Diagnostics Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Multiplexed Diagnostics Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Multiplexed Diagnostics Analysis and Forecast
10.1 Introduction
10.2 North America Multiplexed Diagnostics Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Multiplexed Diagnostics Market Size Forecast by Application
10.6.1 Infectious Disease Diagnostics
10.6.2 Allergies
10.6.3 Autoimmune Diseases
10.6.4 Cardiac Diseases
10.6.5 Oncology
10.7 Basis Point Share (BPS) Analysis by Application
10.8 Absolute $ Opportunity Assessment by Application
10.9 Market Attractiveness Analysis by Application
10.10 North America Multiplexed Diagnostics Market Size Forecast by Technology
10.10.1 Very High Density Multiplexed Assays
10.10.2 Next-Generation Sequencing Assays
10.10.3 High Density Multiplexed Assays
10.10.4 Medium Density Multiplexed Assays
10.10.5 Low Density Multiplexed Assays
10.11 Basis Point Share (BPS) Analysis by Technology
10.12 Absolute $ Opportunity Assessment by Technology
10.13 Market Attractiveness Analysis by Technology
10.14 North America Multiplexed Diagnostics Market Size Forecast by End User
10.14.1 Hospitals
10.14.2 Academic Research Institutes
10.14.3 Diagnostic Laboratories
10.14.4 Pharmaceuticals Companies
10.14.5 Clinical Research Organizations
10.15 Basis Point Share (BPS) Analysis by End User
10.16 Absolute $ Opportunity Assessment by End User
10.17 Market Attractiveness Analysis by End User
Chapter 11 Europe Multiplexed Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Europe Multiplexed Diagnostics Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Multiplexed Diagnostics Market Size Forecast by Application
11.6.1 Infectious Disease Diagnostics
11.6.2 Allergies
11.6.3 Autoimmune Diseases
11.6.4 Cardiac Diseases
11.6.5 Oncology
11.7 Basis Point Share (BPS) Analysis by Application
11.8 Absolute $ Opportunity Assessment by Application
11.9 Market Attractiveness Analysis by Application
11.10 Europe Multiplexed Diagnostics Market Size Forecast by Technology
11.10.1 Very High Density Multiplexed Assays
11.10.2 Next-Generation Sequencing Assays
11.10.3 High Density Multiplexed Assays
11.10.4 Medium Density Multiplexed Assays
11.10.5 Low Density Multiplexed Assays
11.11 Basis Point Share (BPS) Analysis by Technology
11.12 Absolute $ Opportunity Assessment by Technology
11.13 Market Attractiveness Analysis by Technology
11.14 Europe Multiplexed Diagnostics Market Size Forecast by End User
11.14.1 Hospitals
11.14.2 Academic Research Institutes
11.14.3 Diagnostic Laboratories
11.14.4 Pharmaceuticals Companies
11.14.5 Clinical Research Organizations
11.15 Basis Point Share (BPS) Analysis by End User
11.16 Absolute $ Opportunity Assessment by End User
11.17 Market Attractiveness Analysis by End User
Chapter 12 Asia Pacific Multiplexed Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Multiplexed Diagnostics Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Multiplexed Diagnostics Market Size Forecast by Application
12.6.1 Infectious Disease Diagnostics
12.6.2 Allergies
12.6.3 Autoimmune Diseases
12.6.4 Cardiac Diseases
12.6.5 Oncology
12.7 Basis Point Share (BPS) Analysis by Application
12.8 Absolute $ Opportunity Assessment by Application
12.9 Market Attractiveness Analysis by Application
12.10 Asia Pacific Multiplexed Diagnostics Market Size Forecast by Technology
12.10.1 Very High Density Multiplexed Assays
12.10.2 Next-Generation Sequencing Assays
12.10.3 High Density Multiplexed Assays
12.10.4 Medium Density Multiplexed Assays
12.10.5 Low Density Multiplexed Assays
12.11 Basis Point Share (BPS) Analysis by Technology
12.12 Absolute $ Opportunity Assessment by Technology
12.13 Market Attractiveness Analysis by Technology
12.14 Asia Pacific Multiplexed Diagnostics Market Size Forecast by End User
12.14.1 Hospitals
12.14.2 Academic Research Institutes
12.14.3 Diagnostic Laboratories
12.14.4 Pharmaceuticals Companies
12.14.5 Clinical Research Organizations
12.15 Basis Point Share (BPS) Analysis by End User
12.16 Absolute $ Opportunity Assessment by End User
12.17 Market Attractiveness Analysis by End User
Chapter 13 Latin America Multiplexed Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Latin America Multiplexed Diagnostics Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Multiplexed Diagnostics Market Size Forecast by Application
13.6.1 Infectious Disease Diagnostics
13.6.2 Allergies
13.6.3 Autoimmune Diseases
13.6.4 Cardiac Diseases
13.6.5 Oncology
13.7 Basis Point Share (BPS) Analysis by Application
13.8 Absolute $ Opportunity Assessment by Application
13.9 Market Attractiveness Analysis by Application
13.10 Latin America Multiplexed Diagnostics Market Size Forecast by Technology
13.10.1 Very High Density Multiplexed Assays
13.10.2 Next-Generation Sequencing Assays
13.10.3 High Density Multiplexed Assays
13.10.4 Medium Density Multiplexed Assays
13.10.5 Low Density Multiplexed Assays
13.11 Basis Point Share (BPS) Analysis by Technology
13.12 Absolute $ Opportunity Assessment by Technology
13.13 Market Attractiveness Analysis by Technology
13.14 Latin America Multiplexed Diagnostics Market Size Forecast by End User
13.14.1 Hospitals
13.14.2 Academic Research Institutes
13.14.3 Diagnostic Laboratories
13.14.4 Pharmaceuticals Companies
13.14.5 Clinical Research Organizations
13.15 Basis Point Share (BPS) Analysis by End User
13.16 Absolute $ Opportunity Assessment by End User
13.17 Market Attractiveness Analysis by End User
Chapter 14 Middle East & Africa (MEA) Multiplexed Diagnostics Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Multiplexed Diagnostics Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Multiplexed Diagnostics Market Size Forecast by Application
14.6.1 Infectious Disease Diagnostics
14.6.2 Allergies
14.6.3 Autoimmune Diseases
14.6.4 Cardiac Diseases
14.6.5 Oncology
14.7 Basis Point Share (BPS) Analysis by Application
14.8 Absolute $ Opportunity Assessment by Application
14.9 Market Attractiveness Analysis by Application
14.10 Middle East & Africa (MEA) Multiplexed Diagnostics Market Size Forecast by Technology
14.10.1 Very High Density Multiplexed Assays
14.10.2 Next-Generation Sequencing Assays
14.10.3 High Density Multiplexed Assays
14.10.4 Medium Density Multiplexed Assays
14.10.5 Low Density Multiplexed Assays
14.11 Basis Point Share (BPS) Analysis by Technology
14.12 Absolute $ Opportunity Assessment by Technology
14.13 Market Attractiveness Analysis by Technology
14.14 Middle East & Africa (MEA) Multiplexed Diagnostics Market Size Forecast by End User
14.14.1 Hospitals
14.14.2 Academic Research Institutes
14.14.3 Diagnostic Laboratories
14.14.4 Pharmaceuticals Companies
14.14.5 Clinical Research Organizations
14.15 Basis Point Share (BPS) Analysis by End User
14.16 Absolute $ Opportunity Assessment by End User
14.17 Market Attractiveness Analysis by End User
Chapter 15 Competition Landscape
15.1 Multiplexed Diagnostics Market: Competitive Dashboard
15.2 Global Multiplexed Diagnostics Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Illumina Inc.
15.3.2 Hologic Inc.
15.3.3 Abbott Laboratories
15.3.4 Siemens Healthineers
15.3.5 F. Hoffmann-La Roche Ltd.
15.3.6 bioMérieux SA
15.3.7 QIAGEN
15.3.8 Thermo Fisher Scientific Inc.
15.3.9 Bio-Rad Laboratories Inc.
15.3.10 Luminex Corporation
15.3.11 Agilent Technologies
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Multiplexed Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Multiplexed Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Multiplexed Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Multiplexed Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Multiplexed Diagnostics Market Size & Forecast, 2018-2028
4.5.1 Multiplexed Diagnostics Market Size and Y-o-Y Growth
4.5.2 Multiplexed Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Multiplexed Diagnostics Market Analysis and Forecast by Application
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Application
5.1.2 Basis Point Share (BPS) Analysis by Application
5.1.3 Absolute $ Opportunity Assessment by Application
5.2 Multiplexed Diagnostics Market Size Forecast by Application
5.2.1 Infectious Disease Diagnostics
5.2.2 Allergies
5.2.3 Autoimmune Diseases
5.2.4 Cardiac Diseases
5.2.5 Oncology
5.3 Market Attractiveness Analysis by Application
Chapter 6 Global Multiplexed Diagnostics Market Analysis and Forecast by Technology
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Technology
6.1.2 Basis Point Share (BPS) Analysis by Technology
6.1.3 Absolute $ Opportunity Assessment by Technology
6.2 Multiplexed Diagnostics Market Size Forecast by Technology
6.2.1 Very High Density Multiplexed Assays
6.2.2 Next-Generation Sequencing Assays
6.2.3 High Density Multiplexed Assays
6.2.4 Medium Density Multiplexed Assays
6.2.5 Low Density Multiplexed Assays
6.3 Market Attractiveness Analysis by Technology
Chapter 7 Global Multiplexed Diagnostics Market Analysis and Forecast by End User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by End User
7.1.2 Basis Point Share (BPS) Analysis by End User
7.1.3 Absolute $ Opportunity Assessment by End User
7.2 Multiplexed Diagnostics Market Size Forecast by End User
7.2.1 Hospitals
7.2.2 Academic Research Institutes
7.2.3 Diagnostic Laboratories
7.2.4 Pharmaceuticals Companies
7.2.5 Clinical Research Organizations
7.3 Market Attractiveness Analysis by End User
Chapter 8 Global Multiplexed Diagnostics Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Multiplexed Diagnostics Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Multiplexed Diagnostics Analysis and Forecast
10.1 Introduction
10.2 North America Multiplexed Diagnostics Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Multiplexed Diagnostics Market Size Forecast by Application
10.6.1 Infectious Disease Diagnostics
10.6.2 Allergies
10.6.3 Autoimmune Diseases
10.6.4 Cardiac Diseases
10.6.5 Oncology
10.7 Basis Point Share (BPS) Analysis by Application
10.8 Absolute $ Opportunity Assessment by Application
10.9 Market Attractiveness Analysis by Application
10.10 North America Multiplexed Diagnostics Market Size Forecast by Technology
10.10.1 Very High Density Multiplexed Assays
10.10.2 Next-Generation Sequencing Assays
10.10.3 High Density Multiplexed Assays
10.10.4 Medium Density Multiplexed Assays
10.10.5 Low Density Multiplexed Assays
10.11 Basis Point Share (BPS) Analysis by Technology
10.12 Absolute $ Opportunity Assessment by Technology
10.13 Market Attractiveness Analysis by Technology
10.14 North America Multiplexed Diagnostics Market Size Forecast by End User
10.14.1 Hospitals
10.14.2 Academic Research Institutes
10.14.3 Diagnostic Laboratories
10.14.4 Pharmaceuticals Companies
10.14.5 Clinical Research Organizations
10.15 Basis Point Share (BPS) Analysis by End User
10.16 Absolute $ Opportunity Assessment by End User
10.17 Market Attractiveness Analysis by End User
Chapter 11 Europe Multiplexed Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Europe Multiplexed Diagnostics Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Multiplexed Diagnostics Market Size Forecast by Application
11.6.1 Infectious Disease Diagnostics
11.6.2 Allergies
11.6.3 Autoimmune Diseases
11.6.4 Cardiac Diseases
11.6.5 Oncology
11.7 Basis Point Share (BPS) Analysis by Application
11.8 Absolute $ Opportunity Assessment by Application
11.9 Market Attractiveness Analysis by Application
11.10 Europe Multiplexed Diagnostics Market Size Forecast by Technology
11.10.1 Very High Density Multiplexed Assays
11.10.2 Next-Generation Sequencing Assays
11.10.3 High Density Multiplexed Assays
11.10.4 Medium Density Multiplexed Assays
11.10.5 Low Density Multiplexed Assays
11.11 Basis Point Share (BPS) Analysis by Technology
11.12 Absolute $ Opportunity Assessment by Technology
11.13 Market Attractiveness Analysis by Technology
11.14 Europe Multiplexed Diagnostics Market Size Forecast by End User
11.14.1 Hospitals
11.14.2 Academic Research Institutes
11.14.3 Diagnostic Laboratories
11.14.4 Pharmaceuticals Companies
11.14.5 Clinical Research Organizations
11.15 Basis Point Share (BPS) Analysis by End User
11.16 Absolute $ Opportunity Assessment by End User
11.17 Market Attractiveness Analysis by End User
Chapter 12 Asia Pacific Multiplexed Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Multiplexed Diagnostics Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Multiplexed Diagnostics Market Size Forecast by Application
12.6.1 Infectious Disease Diagnostics
12.6.2 Allergies
12.6.3 Autoimmune Diseases
12.6.4 Cardiac Diseases
12.6.5 Oncology
12.7 Basis Point Share (BPS) Analysis by Application
12.8 Absolute $ Opportunity Assessment by Application
12.9 Market Attractiveness Analysis by Application
12.10 Asia Pacific Multiplexed Diagnostics Market Size Forecast by Technology
12.10.1 Very High Density Multiplexed Assays
12.10.2 Next-Generation Sequencing Assays
12.10.3 High Density Multiplexed Assays
12.10.4 Medium Density Multiplexed Assays
12.10.5 Low Density Multiplexed Assays
12.11 Basis Point Share (BPS) Analysis by Technology
12.12 Absolute $ Opportunity Assessment by Technology
12.13 Market Attractiveness Analysis by Technology
12.14 Asia Pacific Multiplexed Diagnostics Market Size Forecast by End User
12.14.1 Hospitals
12.14.2 Academic Research Institutes
12.14.3 Diagnostic Laboratories
12.14.4 Pharmaceuticals Companies
12.14.5 Clinical Research Organizations
12.15 Basis Point Share (BPS) Analysis by End User
12.16 Absolute $ Opportunity Assessment by End User
12.17 Market Attractiveness Analysis by End User
Chapter 13 Latin America Multiplexed Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Latin America Multiplexed Diagnostics Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Multiplexed Diagnostics Market Size Forecast by Application
13.6.1 Infectious Disease Diagnostics
13.6.2 Allergies
13.6.3 Autoimmune Diseases
13.6.4 Cardiac Diseases
13.6.5 Oncology
13.7 Basis Point Share (BPS) Analysis by Application
13.8 Absolute $ Opportunity Assessment by Application
13.9 Market Attractiveness Analysis by Application
13.10 Latin America Multiplexed Diagnostics Market Size Forecast by Technology
13.10.1 Very High Density Multiplexed Assays
13.10.2 Next-Generation Sequencing Assays
13.10.3 High Density Multiplexed Assays
13.10.4 Medium Density Multiplexed Assays
13.10.5 Low Density Multiplexed Assays
13.11 Basis Point Share (BPS) Analysis by Technology
13.12 Absolute $ Opportunity Assessment by Technology
13.13 Market Attractiveness Analysis by Technology
13.14 Latin America Multiplexed Diagnostics Market Size Forecast by End User
13.14.1 Hospitals
13.14.2 Academic Research Institutes
13.14.3 Diagnostic Laboratories
13.14.4 Pharmaceuticals Companies
13.14.5 Clinical Research Organizations
13.15 Basis Point Share (BPS) Analysis by End User
13.16 Absolute $ Opportunity Assessment by End User
13.17 Market Attractiveness Analysis by End User
Chapter 14 Middle East & Africa (MEA) Multiplexed Diagnostics Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Multiplexed Diagnostics Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Multiplexed Diagnostics Market Size Forecast by Application
14.6.1 Infectious Disease Diagnostics
14.6.2 Allergies
14.6.3 Autoimmune Diseases
14.6.4 Cardiac Diseases
14.6.5 Oncology
14.7 Basis Point Share (BPS) Analysis by Application
14.8 Absolute $ Opportunity Assessment by Application
14.9 Market Attractiveness Analysis by Application
14.10 Middle East & Africa (MEA) Multiplexed Diagnostics Market Size Forecast by Technology
14.10.1 Very High Density Multiplexed Assays
14.10.2 Next-Generation Sequencing Assays
14.10.3 High Density Multiplexed Assays
14.10.4 Medium Density Multiplexed Assays
14.10.5 Low Density Multiplexed Assays
14.11 Basis Point Share (BPS) Analysis by Technology
14.12 Absolute $ Opportunity Assessment by Technology
14.13 Market Attractiveness Analysis by Technology
14.14 Middle East & Africa (MEA) Multiplexed Diagnostics Market Size Forecast by End User
14.14.1 Hospitals
14.14.2 Academic Research Institutes
14.14.3 Diagnostic Laboratories
14.14.4 Pharmaceuticals Companies
14.14.5 Clinical Research Organizations
14.15 Basis Point Share (BPS) Analysis by End User
14.16 Absolute $ Opportunity Assessment by End User
14.17 Market Attractiveness Analysis by End User
Chapter 15 Competition Landscape
15.1 Multiplexed Diagnostics Market: Competitive Dashboard
15.2 Global Multiplexed Diagnostics Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Illumina Inc.
15.3.2 Hologic Inc.
15.3.3 Abbott Laboratories
15.3.4 Siemens Healthineers
15.3.5 F. Hoffmann-La Roche Ltd.
15.3.6 bioMérieux SA
15.3.7 QIAGEN
15.3.8 Thermo Fisher Scientific Inc.
15.3.9 Bio-Rad Laboratories Inc.
15.3.10 Luminex Corporation
15.3.11 Agilent Technologies
Segments Covered in the Report
The global Multiplexed Diagnostics market has been segmented based on
By Application
The global Multiplexed Diagnostics market has been segmented based on
By Application
- Infectious Disease Diagnostics
- Allergies
- Autoimmune Diseases
- Cardiac Diseases
- Oncology
- Very High Density Multiplexed Assays
- Next-Generation Sequencing Assays
- High Density Multiplexed Assays
- Medium Density Multiplexed Assays
- Low Density Multiplexed Assays
- Hospitals
- Academic Research Institutes
- Diagnostic Laboratories
- Pharmaceuticals Companies
- Clinical Research Organizations
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Illumina Inc.
- Hologic Inc.
- Abbott Laboratories
- Siemens Healthineers
- F. Hoffmann-La Roche Ltd.
- bioMérieux SA
- QIAGEN
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Luminex Corporation
- Agilent Technologies
Our Clients
Related Reports
Some other reports from this category!
